COX-2 is overexpressed in 40% of cases of invasive breast carcinoma and has been implicated in multiple steps during breast tumor progression, including primary tumor growth, metastasis, angiogenesis, and immune evasion. Here, PTGS2 is linked to breast neoplasm.